Treatment and biomarker testing patterns,treatment outcomes in a/m NSCLC with and without actionable genomic alterations

Inclusion Criteria

• 1. Morphologically confirmed NSCLC with or without actionable genomic alterations (AGA, i.e. EGFR, ALK, ROS1, NTRK, BRAF, MET exon 14 skipping, RET, ERBB2 (HER2), or KRAS)
• 2. Age ≥18 years at the time of NSCLC diagnosis;
• 3. Locally advanced or metastatic disease defined as incident stage IIIB/IIIC/IV NSCLC or stage I–IIIA then progressed to stage IIIB-IV disease and not eligible for curative-intent treatment (the date of progression is included in the database);
• 4. Available data on at least one line of systemic therapy for advanced/metastatic disease within the period since January 2022 until January 2025;
• 5. Patients may be alive or deceased at the time of medical record abstraction